Castle Biosciences Inc (CSTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has a cash flow conversion efficiency ratio of 0.048x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($22.63 Million) by net assets ($467.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Castle Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Castle Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CSTL liabilities breakdown for a breakdown of total debt and financial obligations.
Castle Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Castle Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparebank 1 Ringerike Hadeland
OL:RING
|
0.191x |
|
NOVA Technology Corporation Limited
SHE:300921
|
N/A |
|
Amerigo Resources Ltd.
TO:ARG
|
0.111x |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
0.228x |
|
Montrose Environmental Grp
NYSE:MEG
|
0.061x |
|
SZZT Electronics Co Ltd
SHE:002197
|
0.016x |
|
Guangzhou Pearl River Industrial Development Co Ltd
SHG:600684
|
-0.003x |
|
ZENTIVA S.A.
RO:SCD
|
0.012x |
Annual Cash Flow Conversion Efficiency for Castle Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Castle Biosciences Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Castle Biosciences Inc (CSTL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $455.83 Million | $64.87 Million | 0.142x | +1089.66% |
| 2023-12-31 | $391.27 Million | $-5.63 Million | -0.014x | +86.22% |
| 2022-12-31 | $399.15 Million | $-41.66 Million | -0.104x | -126.35% |
| 2021-12-31 | $411.74 Million | $-18.98 Million | -0.046x | -294.27% |
| 2020-12-31 | $415.69 Million | $9.87 Million | 0.024x | -71.21% |
| 2019-12-31 | $85.11 Million | $7.01 Million | 0.082x | -93.25% |
| 2018-12-31 | $-10.07 Million | $-12.29 Million | 1.221x | +42.44% |
| 2017-12-31 | $-14.27 Million | $-12.23 Million | 0.857x | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a r… Read more